Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2026)
Top general drug manufacturer stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...

Overview Zen Rating Price Value Growth Financials Momentum Sentiment Forecast

General Drug Manufacturers is Zen Rated A and is the 4th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Price	Price Target	Upside/Downside	Consensus	Analysts	Fore. Revenue Growth	Fore. Earnings Growth	Forecast ROE	Forecast ROA
BMY	BRISTOL MYERS SQUIBB CO	$127.02B	$62.14	$64.83	4.33%	Buy	13	-5.41%	8.01%	44.35%	11.69%
MRK	MERCK & CO INC	$366.73B	$148.76	$163.61	9.98%	Strong Buy	18	3.15%	122.59%	56.64%	19.15%
BIIB	BIOGEN INC	$37.67B	$254.87	$265.57	4.20%	Buy	24	3.11%	99.79%	16.30%	9.62%
NVS	NOVARTIS AG	$310.36B	$163.69	$136.00	-16.92%	Sell	2	N/A	N/A	N/A	N/A
GILD	GILEAD SCIENCES INC	$210.01B	$169.32	$174.50	3.06%	Strong Buy	16	4.89%	N/A	116.74%	29.61%
AMGN	AMGEN INC	$251.65B	$465.23	$433.73	-6.77%	Hold	26	4.36%	16.50%	106.15%	15.86%
ABBV	ABBVIE INC	$518.44B	$293.30	$305.57	4.18%	Strong Buy	23	7.34%	47.42%	-771.30%	24.17%
LLY	ELI LILLY & CO	$1.33T	$1,411.95	$1.48k	4.56%	Strong Buy	18	11.97%	25.40%	143.88%	39.13%
AZN	ASTRAZENECA PLC	$293.74B	$189.39	$198.00	4.55%	Buy	1	N/A	N/A	N/A	N/A
SNY	SANOFI	$117.36B	$48.12	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PFE	PFIZER INC	$166.61B	$29.23	$30.36	3.88%	Buy	11	-3.91%	53.52%	14.97%	6.52%
AMRN	AMARIN CORP PLC	$247.40M	$11.74	$13.00	10.73%	Strong Sell	1	-0.08%	N/A	136.39%	95.60%
GRFS	GRIFOLS SA	$5.97B	$8.69	$9.00	3.57%	Hold	1	0.58%	26.59%	18.27%	4.89%
GSK	GSK PLC	$103.31B	$51.54	$55.90	8.46%	Hold	2	N/A	N/A	N/A	N/A
JNJ	JOHNSON & JOHNSON	$679.13B	$282.11	$289.31	2.55%	Strong Buy	13	5.63%	26.94%	46.41%	19.17%
MDCX	MEDICUS PHARMA LTD	$3.62M	$1.89	N/A	N/A	N/A	N/A	N/A	N/A	-679.42%	492.46%
MIRA	MIRA PHARMACEUTICALS INC	$26.01M	$0.62	$3.50	465.43%	Strong Buy	1	N/A	N/A	N/A	N/A
NSRX	NASUS PHARMA LTD	$34.37M	$2.94	$7.00	138.50%	Strong Buy	1	N/A	N/A	-55.40%	-48.94%
SCLX	SCILEX HOLDING CO	$14.78M	$1.74	N/A	N/A	N/A	N/A	162.27%	N/A	-30.63%	37.24%
OGN	ORGANON & CO	$3.64B	$13.85	N/A	N/A	N/A	N/A	3.36%	71.36%	84.49%	7.52%

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Nov 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: C, Momentum: B, Sentiment: B, Safety: B, Financials: B, and AI: B.

Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 50, which is 15 points higher than the general drug manufacturer industry average of 35.

BMY passed 18 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock return 31.49% over the past year, underperforming other general drug manufacturer stocks by -2 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $64.83, an upside of 4.33% from Bristol Myers Squibb Co's current stock price of $62.14.

Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Bristol Myers Squibb Co, 46.15% have issued a Strong Buy rating, 0% have issued a Buy, 46.15% have issued a hold, while 0% have issued a Sell rating, and 7.69% have issued a Strong Sell.

2. Merck & Co (NYSE:MRK)

Merck & Co (NYSE:MRK) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Merck & Co (NYSE:MRK) is: Value: B, Growth: C, Momentum: A, Sentiment: B, Safety: A, Financials: B, and AI: B.

Merck & Co (NYSE:MRK) has a Due Diligence Score of 32, which is -3 points lower than the general drug manufacturer industry average of 35. Although this number is below the industry average, our proven quant model rates MRK as a "A".

MRK passed 11 out of 38 due diligence checks and has average fundamentals. Merck & Co has seen its stock return 71.48% over the past year, overperforming other general drug manufacturer stocks by 38 percentage points.

Merck & Co has an average 1 year price target of $163.61, an upside of 9.98% from Merck & Co's current stock price of $148.76.

Merck & Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 18 analysts covering Merck & Co, 50% have issued a Strong Buy rating, 27.78% have issued a Buy, 22.22% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Biogen (NASDAQ:BIIB) is: Value: B, Growth: B, Momentum: B, Sentiment: C, Safety: B, Financials: C, and AI: C.

Biogen (NASDAQ:BIIB) has a Due Diligence Score of 39, which is 4 points higher than the general drug manufacturer industry average of 35.

BIIB passed 12 out of 33 due diligence checks and has average fundamentals. Biogen has seen its stock return 63.11% over the past year, overperforming other general drug manufacturer stocks by 30 percentage points.

Biogen has an average 1 year price target of $265.57, an upside of 4.2% from Biogen's current stock price of $254.87.

Biogen stock has a consensus Buy recommendation according to Wall Street analysts. Of the 24 analysts covering Biogen, 41.67% have issued a Strong Buy rating, 33.33% have issued a Buy, 20.83% have issued a hold, while 4.17% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) has an annual dividend yield of 5.88%, which is 3 percentage points higher than the general drug manufacturer industry average of 2.46%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 242.3% indicates that its high dividend yield might not be sustainable for the long-term.

2. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) has an annual dividend yield of 4.06%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.46%. Bristol Myers Squibb Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Bristol Myers Squibb Co's dividend has shown consistent growth over the last 10 years.

Bristol Myers Squibb Co's dividend payout ratio of 55.6% indicates that its dividend yield is sustainable for the long-term.

3. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) has an annual dividend yield of 3.67%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.46%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 93.2% indicates that its dividend yield might not be sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 2.51% in the last day, and up 0.81% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are up.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bristol Myers Squibb Co has a valuation score of 43, which is 11 points higher than the general drug manufacturer industry average of 32. It passed 3 out of 7 valuation due diligence checks.

Bristol Myers Squibb Co's stock has gained 31.49% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -2 percentage points.

2. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 43, which is 11 points higher than the general drug manufacturer industry average of 32. It passed 3 out of 7 valuation due diligence checks.

Biogen's stock has gained 63.11% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 30 percentage points.

3. Grifols Sa (NASDAQ:GRFS)

Grifols Sa (NASDAQ:GRFS) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Grifols Sa has a valuation score of 71, which is 39 points higher than the general drug manufacturer industry average of 32. It passed 5 out of 7 valuation due diligence checks.

Grifols Sa's stock has gained 1.05% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -32 percentage points.

Are general drug manufacturer stocks a good buy now?

43.75% of general drug manufacturer stocks rated by analysts are a strong buy right now. On average, analysts expect general drug manufacturer stocks to rise by 2.27% over the next year.

12.5% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 56.25% of general drug manufacturer stocks are rated B (Buy), 25% are rated C (Hold), 6.25% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 44.35x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

General Drug Manufacturer Stocks FAQ

1. Bristol Myers Squibb Co (NYSE:BMY)

2. Merck & Co (NYSE:MRK)

3. Biogen (NASDAQ:BIIB)

1. Pfizer (NYSE:PFE)

2. Bristol Myers Squibb Co (NYSE:BMY)

3. Sanofi (NASDAQ:SNY)

1. Bristol Myers Squibb Co (NYSE:BMY)

2. Biogen (NASDAQ:BIIB)

3. Grifols Sa (NASDAQ:GRFS)

Company

Stock Tools

Stock Ideas